Filing Flows

Filing Flows › Companies › OptimizeRx › Report card

OptimizeRx earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate3 of 3 reports beat the EPS estimate

OptimizeRx (OPRX) beat the analysts' EPS estimate in 3 of its last 3 reports (100%), by +85.1% on average. Next report: Nov 11, 2026, analysts expect EPS $0.16.

Beat rate100% of 3
Average surprise+85.1%
Next reportNov 11, 2026

Report by report

QuarterReportedEPS est.EPS reportedSurpriseRevenue reported
Q2 2026Aug 12, 2026$0.11$0.16+42.9%$20.5M
Q4 2025Mar 5, 2026$0.22$0.51+127.4%$32.2M
Q3 2025Nov 6, 2025$0.04$0.20n/m$26.1M

Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.

Charts

OptimizeRx: EPS reported against the estimateOptimizeRx: EPS reported against the estimateEstimateReported$0.04$0.20Q3 2025$0.22$0.51Q4 2025$0.11$0.16Q2 2026
Latest (Q2 2026): Estimate $0.11, Reported $0.16.

The next report: what to expect → OptimizeRx: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.